Study of andecaliximab for preventing bone growth after spinal cord injury
Part of Bones, joints & muscles, Injuries & trauma clinical trials.
This trial tests a drug called andecaliximab to see if it can stop abnormal bone growth (heterotopic ossification) that sometimes happens after a spinal cord injury. It is for people who are at high risk for this bone growth and aims to prevent it from forming.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 89 years old.
- You had a traumatic spinal cord injury at least 10 days ago.
- You are at risk for abnormal bone growth, which will be checked with scans.
- You can give informed consent or have a legal representative do so.
- You agree to follow the study schedule and procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for spinal cord injury that is given through a spinal tap. It is for people with a recent or past spinal cord injury who are at least 18 years old. The treatment may help improve recovery.
This study tests a new treatment using stem cell exosomes injected into the hip joint for people with early-stage non-traumatic avascular necrosis of the femoral head (a condition where bone tissue in the hip dies due to poor blood supply, not caused by injury). The goal is to see if it is safe and may help improve hip function and pain.
This Phase 2 trial tests sotateltide (PMZ-1620) in people with a recent spinal cord injury. It aims to see whether the drug can improve neurological recovery after injury, especially in certain levels and types of incomplete injuries.
This trial tests whether a new cell therapy (XS228) can help people with recent spinal cord injuries recover function. The cells are given through a spinal tap and are designed to replace damaged nerve cells.
This Phase 1 study tests whether an off-the-shelf stem cell product made from donated umbilical cord tissue is safe for people with spinal cord injury. It mainly looks at side effects and safety, and may help pave the way for future effectiveness studies.
This trial tests a device that delivers a special cell therapy (LCTOPC1) into the spinal cord. It is for people with a recent or chronic spinal cord injury that is severe (no feeling or movement below the injury) or leaves some sensation but no movement.
Hear when a new Heterotopic Ossification (HO) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.